Seek­ing to 'close the loop' in drug dis­cov­ery with ma­chine learn­ing, Catalio-backed biotech emerges from se­mi-stealth

Two years af­ter se­cur­ing seed fund­ing and re­main­ing in a state of “se­mi-stealth,” a San Fran­cis­co biotech keen on com­bin­ing evo­lu­tion and small mol­e­cule dis­cov­ery re­cent­ly bagged a VC round that will let it do just that.

Known as An­a­genex, the com­pa­ny an­nounced Wednes­day that it raised a $30 mil­lion Se­ries A round, se­cur­ing the at­ten­tion of Catalio Cap­i­tal Man­age­ment as lead in­vestor. A few oth­er in­vestors tagged along, such as Lux Cap­i­tal and Khosla Ven­tures.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER